cefmenoxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 538 65085-01-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefmenoxime hydrochloride
  • cefmenoxime
  • cefmenoxime HCl
A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
  • Molecular weight: 511.55
  • Formula: C16H17N9O5S3
  • CLOGP: 0.32
  • LIPINSKI: 2
  • HAC: 14
  • HDO: 3
  • TPSA: 190.81
  • ALOGS: -3.06
  • ROTB: 8
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 130.38 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.65 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.31 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.89 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.45 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.647 Moderate 0.78
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.528 Moderate 0.78
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.178 10^-6 cm/s Moderate 0.78
dh-clint Dog hepatocyte intrinsic clearance 1.419 uL/min/10^6 cells Moderate 0.78
dppb Dog plasma protein binding (% unbound) 62.510 % Moderate 0.78
fcs-ppb Fetal calf serum protein binding (% unbound) 44.500 % Moderate 0.78
herg hERG pIC50 4.211 pIC50 Moderate 0.78
hh-clint Human hepatocyte intrinsic clearance 1.396 uL/min/10^6 cells Moderate 0.78
hlm-clint Human liver microsomal intrinsic clearance 3.899 uL/min/mg protein Moderate 0.78
hppb Human plasma protein binding (% unbound) 29.760 % Moderate 0.78
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK2,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 52
kinase-selectivity-class AXL,CDK9,DYRK1B,EIF2AK3,GRK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,TEK 11
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.985 Moderate 0.78
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.892 Moderate 0.78
mh-clint Mouse hepatocyte intrinsic clearance 2.825 Moderate 0.78
mppb Mouse plasma protein binding (% unbound) 55.900 Moderate 0.78
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.832 Moderate 0.78
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 38.580 % Moderate 0.78
rat-kpuu-brain Rat brain Kpuu 0.008 % Moderate 0.78
rh-clint Rat hepatocyte intrinsic clearance 1.156 uL/min/10^6 cells Moderate 0.78
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.270 % Moderate 0.78
rppb Rat plasma protein binding (% unbound) 30.530 % Moderate 0.78
solubility-dd Solubility at pH 7.4 in DMSO 950.605 uM Moderate 0.78

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1987 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DD05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC S01AA31 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
ATC S02AA18 SENSORY ORGANS
OTOLOGICALS
ANTIINFECTIVES
Antiinfectives
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:66981 ophthalmology drug

Related Drugs by ATC class:

J01DD Third-generation cephalosporins 17 drugs
cefcapenecefdinircefditoren pivoxilcefetametcefiximecefodizimecefoperazonecefotaximecefpiramidecefpodoxime proxetilcefsulodinceftazidime show all 17 →
S01AA Antibiotics 27 drugs
amikacinampicillinazidamfenicolazithromycinbacitracinbenzylpenicillincefuroximechloramphenicolchlortetracyclinedibekacindihydrostreptomycinerythromycin show all 27 →
S02AA Antiinfectives 17 drugs
acetic acidaluminium acetotartrateboric acidchloramphenicolchlorhexidineciprofloxacinclioquinolfosfomycingentamicinhydrogen peroxidemiconazoleneomycin show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.5 acidic
pKa2 13.31 acidic
pKa3 3.23 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
D01739 KEGG_DRUG
75738-58-8 SECONDARY_CAS_RN
C0007549 UMLSCUI
CHEBI:55490 CHEBI
CHEMBL1201224 ChEMBL_ID
CHEMBL3183193 ChEMBL_ID
D015281 MESH_DESCRIPTOR_UI
DB00267 DRUGBANK_ID
12024 IUPHAR_LIGAND_ID
4930 INN_ID
KBZ4844CXN UNII
9570757 PUBCHEM_CID
006821 NDDF
006822 NDDF

Pharmaceutical products:

None